{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:05:48Z","timestamp":1790910348571,"version":"4.1.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.1001\/jamasurg.2019.1165","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T17:13:38Z","timestamp":1558545218000},"page":"697","source":"Crossref","is-referenced-by-count":38,"title":["Assessment of Anti\u2013Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis"],"prefix":"10.1001","volume":"154","author":[{"given":"Christopher J.","family":"Pannucci","sequence":"first","affiliation":[{"name":"Division of Plastic Surgery, University of Utah, Salt Lake City"},{"name":"Division of Health Services Research, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kory I.","family":"Fleming","sequence":"additional","affiliation":[{"name":"Division of Plastic Surgery, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne B.","family":"Bertolaccini","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Prazak","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyen C.","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of General Surgery, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Bartley","family":"Pickron","sequence":"additional","affiliation":[{"name":"Division of General Surgery, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"soi190023r2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/DCR.0000000000000982","article-title":"The American Society of Colon and Rectal Surgeons clinical practice guideline for the prevention of venous thromboembolic disease in colorectal surgery.","volume":"61","author":"Fleming","year":"2018","journal-title":"Dis Colon Rectum"},{"issue":"8","key":"soi190023r3","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1001\/jamasurg.2015.1057","article-title":"Thromboembolic complications and prophylaxis patterns in colorectal surgery.","volume":"150","author":"Nelson","year":"2015","journal-title":"JAMA Surg"},{"issue":"11","key":"soi190023r4","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1245\/s10434-018-6671-7","article-title":"Venous thromboembolic events following major pelvic and abdominal surgeries for cancer: a prospective cohort study.","volume":"25","author":"Serrano","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"soi190023r5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00384-017-2909-2","article-title":"Colorectal cancer and thrombosis.","volume":"33","author":"Rees","year":"2018","journal-title":"Int J Colorectal Dis"},{"issue":"2","key":"soi190023r6","doi-asserted-by":"publisher","first-page":"e227S","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.","volume":"141","author":"Gould","year":"2012","journal-title":"Chest"},{"issue":"13","key":"soi190023r8","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa012385","article-title":"Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.","volume":"346","author":"Bergqvist","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"soi190023r9","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1111\/jth.2006.4.issue-8","article-title":"A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer.","volume":"4","author":"Simonneau","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"3","key":"soi190023r10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/00000658-200103000-00020","article-title":"Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial.","volume":"233","author":"McLeod","year":"2001","journal-title":"Ann Surg"},{"key":"soi190023r11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/s-2007-996425","article-title":"Human pharmacokinetics of low molecular weight heparins.","volume":"25","author":"Cornelli","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"soi190023r12","doi-asserted-by":"publisher","first-page":"489S","DOI":"10.1378\/chest.114.5_Supplement.489S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.","volume":"114","author":"Hirsh","year":"1998","journal-title":"Chest"},{"issue":"2","key":"soi190023r13","doi-asserted-by":"publisher","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"4","key":"soi190023r14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/PRS.0000000000003159","article-title":"Inadequate enoxaparin dosing predicts 90-day venous thromboembolism risk among plastic surgery inpatients: an examination of enoxaparin pharmacodynamics.","volume":"139","author":"Pannucci","year":"2017","journal-title":"Plast Reconstr Surg"},{"key":"soi190023r15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jss.2017.08.053","article-title":"Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery.","volume":"221","author":"Baumgartner","year":"2018","journal-title":"J Surg Res"},{"issue":"2","key":"soi190023r16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.athoracsur.2018.02.085","article-title":"Enoxaparin, 40 mg per day, is inadequate for venous thromboembolism prophylaxis after thoracic surgical procedure.","volume":"106","author":"Pannucci","year":"2018","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"soi190023r17","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1055\/s-0038-1651032","article-title":"The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement.","volume":"62","author":"Levine","year":"1989","journal-title":"Thromb Haemost"},{"issue":"4","key":"soi190023r18","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/TA.0b013e3181d32271","article-title":"Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients.","volume":"68","author":"Malinoski","year":"2010","journal-title":"J Trauma"},{"issue":"6","key":"soi190023r19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.amjsurg.2013.10.005","article-title":"Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer?","volume":"206","author":"Kopelman","year":"2013","journal-title":"Am J Surg"},{"issue":"2","key":"soi190023r20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.amjsurg.2017.07.014","article-title":"Anti-factor Xa measurements in acute care surgery patients to examine enoxaparin dose.","volume":"216","author":"Wall","year":"2018","journal-title":"Am J Surg"},{"issue":"6","key":"soi190023r21","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1097\/PRS.0000000000004379","article-title":"Twice-daily enoxaparin among plastic surgery inpatients: an examination of pharmacodynamics, 90-day venous thromboembolism, and 90-day bleeding.","volume":"141","author":"Pannucci","year":"2018","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"soi190023r22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/BCR.0b013e318204b346","article-title":"Enoxaparin and antifactor Xa levels in acute burn patients.","volume":"32","author":"Lin","year":"2011","journal-title":"J Burn Care Res"},{"issue":"6","key":"soi190023r23","first-page":"1557","article-title":"Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.","volume":"71","author":"Lin","year":"2011","journal-title":"J Trauma"},{"issue":"6","key":"soi190023r24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/BCR.0b013e3182a2a855","article-title":"Evaluation of an enoxaparin dosing calculator using burn size and weight.","volume":"34","author":"Faraklas","year":"2013","journal-title":"J Burn Care Res"},{"issue":"7","key":"soi190023r25","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/ajh.23228","article-title":"Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.","volume":"87","author":"Freeman","year":"2012","journal-title":"Am J Hematol"},{"issue":"3","key":"soi190023r26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.thromres.2009.02.003","article-title":"Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients.","volume":"125","author":"Rondina","year":"2010","journal-title":"Thromb Res"},{"issue":"6","key":"soi190023r27","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.amjsurg.2016.08.010","article-title":"Utility of anti-factor Xa monitoring in surgical patients receiving prophylactic doses of enoxaparin for venous thromboembolism prophylaxis.","volume":"213","author":"Pannucci","year":"2017","journal-title":"Am J Surg"},{"issue":"2","key":"soi190023r28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.surg.2016.07.038","article-title":"Should we be following anti-factor Xa levels in patients receiving prophylactic enoxaparin perioperatively?","volume":"161","author":"Pannucci","year":"2017","journal-title":"Surgery"},{"issue":"2-3","key":"soi190023r29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.disamonth.2005.02.003","article-title":"Thrombosis risk assessment as a guide to quality patient care.","volume":"51","author":"Caprini","year":"2005","journal-title":"Dis Mon"},{"issue":"6","key":"soi190023r30","doi-asserted-by":"publisher","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition).","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"issue":"5","key":"soi190023r31","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.jamcollsurg.2014.01.046","article-title":"Inadequate venous thromboembolism risk stratification predicts venous thromboembolic events in surgical intensive care unit patients.","volume":"218","author":"Pannucci","year":"2014","journal-title":"J Am Coll Surg"},{"issue":"1","key":"soi190023r32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jss.2016.06.049","article-title":"Venous thromboembolism prophylaxis in neurosurgical trauma patients.","volume":"205","author":"Tracy","year":"2016","journal-title":"J Surg Res"},{"issue":"7","key":"soi190023r33","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1177\/000313481508100725","article-title":"Association between interruptions in chemical prophylaxis and VTE formation.","volume":"81","author":"Ramanathan","year":"2015","journal-title":"Am Surg"},{"issue":"1","key":"soi190023r34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jvs.2017.06.087","article-title":"The association of venous thromboembolism chemoprophylaxis timing on venous thromboembolism after major vascular surgery.","volume":"67","author":"Sutzko","year":"2018","journal-title":"J Vasc Surg"},{"issue":"6","key":"soi190023r35","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jamcollsurg.2007.02.072","article-title":"Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study.","volume":"204","author":"Rogers","year":"2007","journal-title":"J Am Coll Surg"},{"issue":"4","key":"soi190023r36","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/SLA.0000000000000340","article-title":"A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer.","volume":"259","author":"Vedovati","year":"2014","journal-title":"Ann Surg"},{"issue":"11","key":"soi190023r37","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1111\/jth.2006.4.issue-11","article-title":"Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study.","volume":"4","author":"Rasmussen","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"6","key":"soi190023r38","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.surg.2018.05.028","article-title":"Extended versus conventional thromboprophylaxis after major abdominal and pelvic surgery: systematic review and meta-analysis of randomized clinical trials.","volume":"164","author":"Rausa","year":"2018","journal-title":"Surgery"},{"issue":"5","key":"soi190023r39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.soard.2007.11.010","article-title":"Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.","volume":"4","author":"Borkgren-Okonek","year":"2008","journal-title":"Surg Obes Relat Dis"},{"issue":"6","key":"soi190023r40","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1097\/AOG.0000000000000873","article-title":"Enoxaparin dosing after cesarean delivery in morbidly obese women.","volume":"125","author":"Overcash","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"6","key":"soi190023r41","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/000313481508100625","article-title":"Prospective Evaluation of weight-based prophylactic enoxaparin dosing in critically ill trauma patients: adequacy of antiXa levels is improved.","volume":"81","author":"Nunez","year":"2015","journal-title":"Am Surg"},{"issue":"6","key":"soi190023r42","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/TA.0000000000001142","article-title":"If some is good, more is better: an enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis.","volume":"81","author":"Berndtson","year":"2016","journal-title":"J Trauma Acute Care Surg"},{"issue":"4","key":"soi190023r43","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ijoa.2013.05.008","article-title":"Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study.","volume":"22","author":"Hiscock","year":"2013","journal-title":"Int J Obstet Anesth"},{"issue":"11","key":"soi190023r44","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jamasurg.2016.1662","article-title":"Association between enoxaparin dosage adjusted by anti-factor Xa trough level and clinically evident venous thromboembolism after trauma.","volume":"151","author":"Ko","year":"2016","journal-title":"JAMA Surg"},{"key":"soi190023r45","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijsu.2018.01.023","article-title":"Trauma patients with lower extremity and pelvic fractures: should anti-factor Xa trough level guide prophylactic enoxaparin dose?","volume":"51","author":"Dhillon","year":"2018","journal-title":"Int J Surg"},{"key":"soi190023r7","year":"2013"},{"key":"soi190023r1","unstructured":"US Department of Health and Human Services. The Surgeon General\u2019s call to action to prevent deep vein thrombosis and pulmonary embolism. http:\/\/www.surgeongeneral.gov\/library\/calls\/index.html. Accessed November 8, 2018."},{"key":"soi190023r46","unstructured":"The Royal College of Obstetricians and Gynecologists. Reducing the risk of venous thromboembolism in pregnancy and the puerperium. https:\/\/www.rcog.org.uk\/globalassets\/documents\/guidelines\/gtg-37a.pdf. Accessed November 8, 2018."}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/article-pdf\/154\/8\/697\/17824171\/jamasurgery_pannucci_2019_oi_190023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T04:42:17Z","timestamp":1607920937000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2734658"}},"subtitle":["A Clinical Study Examining Enoxaparin Pharmacokinetics"],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2019.1165","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,1]]}}}